Chase Investment Counsel Corp Buys New Stake in Halozyme Therapeutics, Inc. $HALO

Chase Investment Counsel Corp bought a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 26,000 shares of the biopharmaceutical company’s stock, valued at approximately $2,035,000.

A number of other hedge funds also recently bought and sold shares of the company. Measured Wealth Private Client Group LLC lifted its position in shares of Halozyme Therapeutics by 51.5% during the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 124 shares during the last quarter. Larson Financial Group LLC increased its position in Halozyme Therapeutics by 3,118.2% in the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 343 shares during the period. Harbour Investments Inc. increased its position in Halozyme Therapeutics by 152.5% in the 4th quarter. Harbour Investments Inc. now owns 616 shares of the biopharmaceutical company’s stock worth $41,000 after buying an additional 372 shares during the period. Clearstead Advisors LLC lifted its holdings in shares of Halozyme Therapeutics by 64.8% during the fourth quarter. Clearstead Advisors LLC now owns 842 shares of the biopharmaceutical company’s stock worth $57,000 after buying an additional 331 shares during the last quarter. Finally, Wexford Capital LP acquired a new position in shares of Halozyme Therapeutics during the third quarter worth approximately $70,000. 97.79% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on HALO. UBS Group restated a “buy” rating and issued a $90.00 price objective on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Citigroup reiterated a “market outperform” rating on shares of Halozyme Therapeutics in a research note on Friday, August 7th. Wall Street Zen raised shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 8th. HC Wainwright increased their price target on shares of Halozyme Therapeutics from $95.00 to $115.00 and gave the company a “buy” rating in a report on Friday, August 7th. Finally, Citizens Jmp raised their price target on shares of Halozyme Therapeutics from $92.00 to $93.00 and gave the stock a “market outperform” rating in a research report on Friday, August 7th. Nine investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $91.20.

Insider Buying and Selling at Halozyme Therapeutics

In related news, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $67.58, for a total transaction of $1,351,600.00. Following the completion of the transaction, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at $51,886,572.40. This trade represents a 2.54% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of the business’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $102.80, for a total transaction of $167,152.80. Following the completion of the transaction, the director owned 40,418 shares in the company, valued at approximately $4,154,970.40. This trade represents a 3.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 44,103 shares of company stock valued at $3,142,896. 2.50% of the stock is currently owned by company insiders.

Halozyme Therapeutics Price Performance

Shares of HALO opened at $98.66 on Monday. The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50. The company has a 50-day moving average price of $79.66 and a two-hundred day moving average price of $72.56. The stock has a market cap of $11.20 billion, a price-to-earnings ratio of 29.45, a P/E/G ratio of 0.40 and a beta of 0.85. Halozyme Therapeutics, Inc. has a 12 month low of $61.22 and a 12 month high of $104.78.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.79 by $0.49. The business had revenue of $481.00 million during the quarter, compared to analysts’ expectations of $402.28 million. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.Halozyme Therapeutics’s quarterly revenue was up 47.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Equities analysts predict that Halozyme Therapeutics, Inc. will post 7.77 EPS for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.